Welcome to the fourteenth edition of The Weekly Briefing. We are back after a short break.
Each week, we break down the most interesting commercial stories shaping the market, from dealmaking to regulation, and explain why they matter for businesses and law firms.
The aim is simple. Build commercial awareness with a clear legal lens.
1. EU Rethinks Merger Rules
The European Commission is planning its biggest change to merger rules in decades.
The goal: help European companies get bigger.
Regulators will look beyond prices and competition and focus more on innovation, investment, and resilience.
This comes after years of criticism that strict rules stopped Europe building companies big enough to compete with the US and China.
For businesses, this could unlock more large deals.
For lawyers, merger control becomes more strategic.
My takeaway
Reactions has been mixed.
More consolidation could help European companies scale. But it can also mean fewer competitors and over time, fewer jobs and less innovation.
The details matter, and right now they’re unclear.
Does this affect the UK?
Not directly. The UK has its own competition regime post-Brexit.
But large deals often need approval in multiple jurisdictions. If the EU becomes more flexible, it could still shape how deals and legal strategy are approached globally.
Why this matters
This is a shift in how merger law works.
Companies won’t just defend deals on competition anymore they’ll argue scale.
For lawyers, that means moving from pure economics to strategy.
2. Lilly Expands Into Sleep Disorders
Kirkland and Ellis advised Eli Lilly and Company on the aqusition of Centessa Pharmaceuticals to expand into sleep and wake disorder treatments.
The deal focuses on Centessa’s clinical-stage drugs targeting conditions like narcolepsy an area with growing demand but limited effective treatments.
For Lilly, it’s a strategic move. It builds on its strength in neuroscience while entering a market with clear unmet need.
My takeaway
This is classic pharma M&A activity. If the drugs succeed, the upside is huge. If they fail, the value disappears.
Why this matters
Pharma deals often hinge on what hasn’t happened yet.
That puts pressure on legal teams to manage risk around clinical trials, regulatory approvals, and IP.
3. UAE Buys Into British Hospitality
An Abu Dhabi-backed investor has acquired one of the UK’s most iconic hospitality groups for £1.4bn. Firms including Herbert Smith Freehills Kramer and Norton Rose Fulbright advised on the deal.
The portfolio includes brands like Annabel’s, The Ivy, and Sexy Fish. Names built on reputation as much as revenue. The strategy is clear. Buy a British brand. Scale it globally.
Plans are already in motion, with Annabel’s heading to New York and The Ivy expanding into the US.
Richard Caring is staying on suggesting the value lies in the brand, not just the business.
My takeaway
What’s interesting here isn’t just the brands it’s the structure behind the deal.
Richard Caring is staying on, which usually signals some form of earn-out or performance-linked incentive. The exact terms aren’t public, but his continued involvement suggests the buyers are relying on him to protect and grow the brand.
We’ve seen a similar playbook before. Capital from the Gulf buying established UK names then scaling them globally.
The question is whether that strategy works in hospitality.
Expanding a brand like Annabel’s or The Ivy isn’t just about opening new locations. It’s about replicating something tied to place, reputation, and exclusivity.